五洲医疗 reported revenue of ¥0.20B for the period ended 2026-06-30, -6.4% year on year. Net income was ¥0.02B, a 7.6% net margin on a 18.1% gross margin. The largest revenue line is 注射器 at 43% of the total. Free cash flow for the period was ¥0.02B.
| Item | Amount | Y/Y |
|---|---|---|
| Revenue | ¥0.20B | -6.4% |
| Gross profit | ¥0.04B | — |
| Operating income | ¥0.02B | — |
| Net income | ¥0.02B | +46.1% |
| Gross margin | 18.1% | Net margin 7.6% |
| Revenue Q/Q | +1.8% | — |
| Segment | Revenue | Share |
|---|---|---|
| 注射器 | ¥0.09B | 43.2% |
| 医用穿刺针 | ¥0.07B | 32.6% |
| 输液输血器 | ¥0.03B | 14.8% |
| 其他 | ¥0.02B | 9.5% |
| Item | Amount | % of revenue |
|---|---|---|
| Cost of revenue | ¥0.17B | 81.9% |
| R&D | ¥0.00B | 2.2% |
| SG&A | ¥0.02B | 8.1% |
| Tax & other | ¥0.00B | 1.0% |
| Item | Amount |
|---|---|
| Total assets | ¥0.86B |
| Total liabilities | ¥0.09B |
| Shareholders' equity | ¥0.76B |
| Equity / assets | 89.2% |
| Operating cash flow | ¥0.03B |
| Capital expenditure | ¥0.01B |
| Free cash flow | ¥0.02B |
| Cash conversion (OCF / net income) | 185% |
The Sankey chart shows how revenue splits into cost of revenue, R&D and SG&A, and what remains as profit — clean visuals for research decks and social posts.
华康洁净 ・ 和顺科技 ・ 瑞泰新材 ・ 普瑞眼科 ・ 宏源药业 ・ 杰创智能 ・ 威尔高 ・ 同星科技 ・ 通力科技 ・ 华融化学 ・ 普蕊斯 ・ 富士莱
Source: Eastmoney · This page shows public filing data only, not investment advice. · Browse all companies